Association between renal iron accumulation and renal interstitial fibrosis in a rat model of chronic kidney disease

Hypertension Research

Volumn 38, Issue 7, 2015, Pages 463-470

  Naito, Yoshiro ^a   Fujii, Aya ^a   Sawada, Hisashi ^a   Oboshi, Makiko ^a   Iwasaku, Toshihiro ^a   Okuhara, Yoshitaka ^a   Morisawa, Daisuke ^a   Eguchi, Akiyo ^a   Hirotani, Shinichi ^a   Masuyama, Tohru ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

chronic kidney disease; iron; renal fibrosis

Indexed keywords

CD68 ANTIGEN; COLLAGEN TYPE 3; CREATININE; DEFERASIROX; HEMOGLOBIN; IRON; MONOCYTE CHEMOTACTIC PROTEIN 1; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UVOMORULIN; VIMENTIN; BENZOIC ACID DERIVATIVE; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; GLOMERULOSCLEROSIS; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HYPERTENSION; IRON BLOOD LEVEL; IRON CHELATION; KIDNEY FIBROSIS; MALE; NEPHRECTOMY; NONHUMAN; NORMOCHROMIC NORMOCYTIC ANEMIA; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSMISSION ELECTRON MICROSCOPY; UREA NITROGEN BLOOD LEVEL; URINE VOLUME; ANIMAL; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; DRUG EFFECTS; FIBROSIS; GENE EXPRESSION; GENETICS; INTERSTITIAL NEPHRITIS; KIDNEY; METABOLISM; PATHOLOGY; PROTEINURIA; SPRAGUE DAWLEY RAT;

ANIMALS; BENZOATES; BLOOD PRESSURE; FIBROSIS; GENE EXPRESSION; IRON; IRON CHELATING AGENTS; KIDNEY; MALE; NEPHRECTOMY; NEPHRITIS, INTERSTITIAL; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY; RENAL INSUFFICIENCY, CHRONIC; TRIAZOLES;

EID: 84936102088     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2015.14     Document Type: Article

References (34)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305
2. Quaggin SE, Kapus A. Scar wars: mapping the fate of epithelial-mesenchymalmyofibroblast transition. Kidney Int 2011; 80: 41-50
3. Nankivell BJ, Boadle RA, Harris DC. Iron accumulation in human chronic renal disease. Am J Kidney Dis 1992; 20: 580-584
4. Wang H, Nishiya K, Ito H, Hosokawa T, Hashimoto K, Moriki T. Iron deposition in renal biopsy specimens from patients with kidney diseases. Am J Kidney Dis 2001; 38: 1038-1044
5. Izuhara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K, van Ypersele de Strihou C, Miyata T. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol 2005; 16: 3631-3641
6. Nankivell BJ, Chen J, Boadle RA, Harris DC. The role of tubular iron accumulation in the remnant kidney. J Am Soc Nephrol 1994; 4: 1598-1607
7. Harris DC, Tay C, Nankivell BJ. Lysosomal iron accumulation and tubular damage in rat puromycin nephrosis and ageing. Clin Exp Pharmacol Physiol 1994; 21: 73-81
8. Naito Y, Sawada H, Oboshi M, Fujii A, Hirotani S, Iwasaku T, Okuhara Y, Eguchi A, Morisawa D, Ohyanagi M, Tsujino T, Masuyama T. Increased renal iron accumulation in hypertensive nephropathy of salt-loaded hypertensive rats. PLoS ONE 2013; 8: e75906
9. Bolli R, Patel BS, Jeroudi MO, Li XY, Triana JF, Lai EK, McCay PB. Iron-mediated radical reactions upon reperfusion contribute to myocardial "stunning". Am J Physiol 1990; 259: H1901-H1911
10. Reddy BR, Kloner RA, Przyklenk K. Early treatment with deferoxamine limits myocardial ischemic/reperfusion injury. Free Radic Biol Med 1989; 7: 45-52
11. Ritter C, Reinke A, Andrades M, Martins MR, Rocha J, Menna-Barreto S, Quevedo J, Moreira JC, Dal-Pizzol F. Protective effect of N-acetylcysteine and deferoxamine on carbon tetrachloride-induced acute hepatic failure in rats. Crit Care Med 2004; 32: 2079-2083
12. Bulucu F, Oktenli C, Kenar L, Ocal R, Koc B, Inal V, Yamanel L, Yaman H, Sanisoglu YS, Aydin A. Efficacy of deferoxamine, N-acetylcysteine and selenium treatments in rats with adriamycin-induced nephrotic syndrome. J Nephrol 2008; 21: 576-583
13. Molina-Jijón E, Zarco-Márquez G, Medina-Campos ON, Zataraín-Barrón ZL, Hernández-Pando R, Pinzón E, Zavaleta RM, Tapia E, Pedraza-Chaverri J. Deferoxamine pretreatment prevents Cr(VI)-induced nephrotoxicity and oxidant stress: role of Cr(VI) chelation. Toxicology 2012; 291: 93-101
14. Rajapurkar MM, Hegde U, Bhattacharya A, Alam MG, Shah SV. Effect of deferiprone, an oral iron chelator, in diabetic and non-diabetic glomerular disease. Toxicol Mech Methods 2013; 23: 5-10
15. Naito Y, Fujii A, Sawada H, Hirotani S, Iwasaku T, Eguchi A, Ohyanagi M, Tsujino T, Masuyama T. Effect of iron restriction on renal damage and mineralocorticoid receptor signaling in a rat model of chronic kidney disease. J Hypetens 2012; 30: 2192-2201
16. Naito Y, Hirotani S, Sawada H, Akahori H, Tsujino T, Masuyama T. Dietary iron restriction prevents hypertensive cardiovascular remodeling in Dahl salt-sensitive rats. Hypertension 2011; 57: 497-504
17. Chen X, Mori T, Guo Q, Hu C, Ohsaki Y, Yoneki Y, Zhu W, Jiang Y, Endo S, Nakayama K, Ogawa S, Nakayama M, Miyata T, Ito S. Carbonyl stress induces hypertension and cardio-renal vascular injury in Dahl salt-sensitive rats. Hypertens Res 2013; 36: 361-367
18. Naito Y, Fujii A, Sawada H, Hirotani S, Iwasaku T, Okuhara Y, Eguchi A, Ohyanagi M, Tsujino T, Masuyama T. Dietary iron restriction prevents further deterioration of renal damage in a chronic kidney disease rat model. J Hypetens 2013; 31: 1203-1213
19. Hošková L, Málek I, Kautzner J, Honsová E, van Dokkum RP, Husková Z, Vojtíšková A, Varcabová S, Cervenka L, Kopkan L. Tacrolimus-induced hypertension and nephrotoxicity in Fawn-Hooded rats are attenuated by dual inhibition of renin-angiotensin system. Hypertens Res 2014; 37: 724-732
20. Pillebout E, Weitzman JB, Burtin M, Martino C, Federici P, Yaniv M, Friedlander G, Terzi F. JunD protects against chronic kidney disease by regulating paracrine mitogens. J Clin Invest 2003; 112: 843-852
21. Sato M, Muragaki Y, Saika S, Roberts AB, Ooshima A. Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 2003; 112: 1486-1494
22. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, Himmelfarb J. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004; 65: 1009-1016
23. Rodríguez-Iturbe B, García García G. The role of tubulointerstitial inflammation in the progression of chronic renal failure. Nephron Clin Pract 2010; 116: c81-c88
24. Viau A, El Karoui K, Laouari D, Burtin M, Nguyen C, Mori K, Pillebout E, Berger T, Mak TW, Knebelmann B, Friedlander G, Barasch J, Terzi F. Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. J Clin Invest 2010; 120: 4065-4076
25. Goraya N, Simoni J, Jo C, Wesson DE. Dietary acid reduction with fruits and vegetables or bicarbonate attenuates kidney injury in patients with a moderately reduced glomerular filtration rate due to hypertensive nephropathy. Kidney Int 2012; 81: 86-93
26. Martines AM, Masereeuw R, Tjalsma H, Hoenderop JG, Wetzels JF, Swinkels DW. Iron metabolism in the pathogenesis of iron-induced kidney injury. Nat Rev Nephrol 2013; 9: 385-398
27. Ikeda Y, Ozono I, Tajima S, Imao M, Horinouchi Y, Izawa-Ishizawa Y, Kihira Y, Miyamoto L, Ishizawa K, Tsuchiya K, Tamaki T. Iron chelation by deferoxamine prevents renal interstitial fibrosis in mice with unilateral ureteral obstruction. PLoS ONE 2014; 9: e89355
28. Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 1992; 20: 1-7
29. Gill PS, Wilcox CS. NADPH oxidases in the kidney. Antioxid Redox Signal 2006; 8: 1597-1607
30. Maker GL, Siva B, Batty KT, Trengove RD, Ferrari P, Olynyk JK. Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis. Nephrology (Carlton) 2013; 18: 188-193
31. Breccia M, Alimena G. Efficacy and safety of deferasirox in myelodysplastic syndromes. Ann Hematol 2013; 92: 863-870
32. Kontoghiorghes GJ. Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities. Expert Opin Drug Saf 2010; 9: 633-641
33. Murphy N, Elramah M, Vats H, Zhong W, Chan MR. A case report of deferasirox-induced kidney injury and Fanconi syndrome. WMJ 2013; 112: 177-180
34. Sánchez-González PD, López-Hernandez FJ, Morales AI, Macías-Nuñez JF, López-Novoa JM. Effects of deferasirox on renal function and renal epithelial cell death. Toxicol Lett 2011; 203: 154-161